EVERNORTH HEALTH SERVICES

Express Scripts® Pharmacy Benefit Services
Pharmacy and Therapeutics (P&T) Committee
Proceedings
March 28, 2026

New Drug Evaluations

The Committee reviewed the following new drugs:

A. **Adquey™ (difamilast 1% ointment)** Acrotech
B. **Bysanti™ (milsaperidone tablets)** Vanda
C. **Icotyde™ (icotrokinra tablets)** Janssen/Johnson & Johnson/Protagonist
D. **Loargys™ (pegzilarginase-nbln intravenous infusion and subcutaneous injection)** Immedica
E. **Nereus™ (tradipitant capsules)** Vanda
F. **Nuzolvence® (zoliflodacin oral suspension)** Entasis
G. **Pivya™ (pivmecillinam tablets)** Alembic
H. **Waskyra® (etuvetidigene autotemcel intravenous infusion)** Fondazione Telethon
I. **Yuviwel® (navepegritide subcutaneous injection)** Ascendis
J. **Zycubo™ (copper histidinate subcutaneous injection)** Sentynl

New Indications for Existing Products

The Committee reviewed the following new or changes to indications for existing products: See product inserts for specific wording.

A. **Braftovi® (encorafenib capsules)** Array – Conversion of accelerated approval to traditional (regular) approval for the treatment of metastatic colorectal cancer with a BRAF V600E mutation in combination with cetuximab intravenous (IV) [Erbitux®] and fluorouracil-based chemotherapy in adults.
B. **Cerezyme® (imiglucerase intravenous infusion)** Genzyme – Expanded indication to include Type 3 Gaucher disease, expanded age indication to include pediatric patients < 2 years of age with Type 1 Gaucher disease, and revised indication specifying treatment of non-central nervous system (CNS) manifestations. Cerezyme is now indicated for the treatment of non-CNS manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients.
C. **Darzalex Faspro® (daratumumab and hyaluronidase-fihj subcutaneous injection)** Janssen – New indication for newly diagnosed multiple myeloma. Darzalex Faspro is now indicated for the treatment of multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed adults who are ineligible for autologous stem cell transplant.
D. **Dupixent® (dupliumab subcutaneous injection)** Regeneron/Sanofi – New indication for the treatment of allergic fungal rhinosinusitis (AFRS) in adults and pediatric patients ≥ 6 years of age who have a history of sino-nasal surgery.
E. **Enzeevu® (aflibercept-abzv intravitreal injection)** Sandoz – New indication for macular edema following retinal vein occlusion; new indication for diabetic macular edema; and new indication for diabetic retinopathy.
F. **Hernexeos® (zongertinib tablets)** Boehringer Ingelheim – Expanded indication for earlier treatment of unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

Hernexeos is now indicated for the treatment unresectable or metastatic non-squamous NSCLC in adults whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

G. **Juxtapid® (lomitapide capsules)** Chiesi – Expanded age indication to include pediatric patients ≥ 2 years of age with homozygous familial hypercholesterolemia (HoFH). Juxtapid is now indicated as an adjunct to a low-fat diet and exercise and other low-density lipoprotein cholesterol (LDL-C) therapies to reduce LDL-C in adults and pediatric patients ≥ 2 years of age with HoFH.

H. **Keytruda® (pembrolizumab intravenous infusion)** and **Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection)** Merck – New indication for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults, in combination with paclitaxel, with or without bevacizumab, whose tumors express programmed death-ligand 1 (combined positive score ≥ 1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

I. **Leqvio® (inclisiran subcutaneous injection)** Novartis – Expanded age indication for pediatric patients ≥ 12 years of age with heterozygous familial hypercholesterolemia (HeFH). Leqvio is now indicated as an adjunct to diet and exercise to reduce LDL-C in adults and pediatric patients ≥ 12 years of age with HeFH. Additionally, Leqvio received a new indication for pediatric patients ≥ 12 years of age with HoFH. Leqvio is now indicated as an adjunct to diet and exercise to reduce LDL-C in pediatric patients ≥ 12 years of age with HoFH.

J. **Nexplanon® (etonogestrel subdermal implant)** Organon – Extended duration of use for the prevention of pregnancy for up to 5 years. Nexplanon is now indicated for the prevention of pregnancy in women of reproductive potential for up to 5 years.

K. **Noxafil® (posaconazole delayed-release tablets)** Merck – Expanded age indication to include pediatric patients ≥ 2 years of age who weigh > 40 kg. Noxafil delayed-release tablets are now indicated for the treatment of invasive aspergillosis in adults and pediatric patients ≥ 2 years of age who weigh > 40 kg.

L. **Noxafil® PowderMix (posaconazole delayed-release oral suspension)** Merck – New indication for the treatment of invasive aspergillosis in pediatric patients ≥ 2 years of age who weigh 10 kg to 40 kg. The agent also received a revised indication to specify a minimum weight for the prophylaxis of invasive Aspergillus and Candida infections for pediatric patients. Noxafil PowderMix is now indicated for the prophylaxis of invasive Aspergillus and Candida infections in pediatric patients ≥ 2 years of age who weigh 10 kg to 40 kg who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

M. **Ozempic® (semaglutide tablets)** Novo Nordisk – Revised labeling to reflect a proprietary name change from Rybelsus® (semaglutide tablets). The FDA approved a name change from Rybelsus 1.5 mg, 4 mg and 9 mg (previously "R2" Rybelsus) to Ozempic tablet 1.5 mg, 4 mg and 9 mg. Rybelsus 3 mg, 7 mg, and 14 mg tablets remain available on the market at this time.

N. **Palynziq® (pegvaliase-pqpz subcutaneous injection)** BioMarin – Expanded age indication to include pediatric patients with phenylketonuria (PKU) ≥ 12 years of age. Palynziq is now indicated to reduce blood phenylalanine (Phe) concentrations in adults and pediatric patients ≥ 12 years of age with PKU who have uncontrolled blood Phe concentrations > 600 micromol/L on existing management.

O. **Prezcobix® (darunavir and cobicistat tablets)** and **Prezcobix® PED (darunavir and cobicistat tablets for oral suspension)** Janssen – Expanded age and weight indication of Prezcobix for the treatment of human immunodeficiency virus (HIV-1) in pediatric patients ≥ 3 years of age weighing ≥ 15 kg. Prezcobix is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 in treatment-naïve and treatment-experienced adults and pediatric patients ≥ 3 years of age weighing ≥ 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V).

P. **RizaFilm™ (rizatriptan oral film)** IntelGenx – Expanded age indication for acute treatment of migraine to include pediatric patients 6 years to 11 years of age. RizaFilm is now indicated for the acute treatment of migraine with or without aura in adults and pediatric patients ≥ 6 years of age.

Q. **Sogroya® (somapacitan-beco subcutaneous injection)** Novo Nordisk – New indication for the treatment of pediatric patients ≥ 2.5 years of age with short stature born small for gestational age and with no catch-up growth by 2 years of age. The agent also received a new indication for the treatment of pediatric patients ≥ 2.5 years of age with growth failure associated with Noonan syndrome. Sogroya also received another new indication for the treatment of pediatric patients ≥ 2.5 years of age with idiopathic short stature.

R. **Sotyktu™ (deucravacitinib tablets)** Bristol Myers Squibb – New indication for the treatment of active psoriatic arthritis in adults. Sotyktu is now indicated for the treatment of active psoriatic arthritis in adults.

S. **Tecvayli® (teclistamab-cqyv subcutaneous injection)** Janssen – New indication for multiple myeloma in combination with Darzalex Faspro® (daratumumab hyaluronidase-fihj SC injection) as a second-line therapy. Tecvayli is now indicated for the treatment of relapsed or refractory multiple myeloma in adults in combination with Darzalex Faspro in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Also, there was a conversion from accelerated approval to traditional approval as monotherapy, in relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

T. **Wakix® (pitolisant tablets)** Harmony Biosciences – Expanded age indication for the treatment of cataplexy in patients ≥ 6 years of age with narcolepsy. Wakix is now indicated for the treatment of excessive daytime sleepiness or cataplexy in patients ≥ 6 years of age with narcolepsy.

U. **Wellcovorin® (leucovorin calcium tablets)** GlaxoSmithKline – New indication for the treatment of cerebral folate transport deficiency in adults and pediatric patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD).

V. **Yescarta® (axicabtagene ciloleucel intravenous infusion)** Kite – Expanded indication to remove the Limitation of Use that Yescarta is not indicated for the treatment of patients with primary CNS lymphoma. Yescarta is now indicated for large B-cell lymphoma (LBCL) in adults that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy and for relapsed or refractory LBCL in adults after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal LBCL, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions:

A. **Avopef™ (etoposide intravenous infusion)** Avyxa Pharma

B. **Desmoda™ (desmopressin acetate oral solution)** Eton
C. **Favlyxa™ (fluorouracil intravenous)** Avyxa Pharma
D. **Prezcobix® PED (darunavir and cobicistat tablets for oral suspension)** Janssen
E. **Quiofic™ (folic acid oral solution)** Solubiomix
F. **Vybrique™ (sildenafil oral film)** IBSA Pharma
G. **Vykoura™ (leucovorin calcium injection)** Avyxa Pharma

New Biosimilars

The Committee reviewed the following new biosimilars:

A. **Filkri® (filgrastim-hala subcutaneous and intravenous infusion)** Accord